# Molecular Biology and Evolution of Cancer: From Discovery to Action

Jason A. Somarelli,<sup>1,2</sup> Heather Gardner,<sup>3</sup> Vincent L. Cannataro ,<sup>4</sup> Ella F. Gunady,<sup>1</sup> Amy M. Boddy,<sup>5</sup> Norman A. Johnson,<sup>6</sup> Jeffrey Nicholas Fisk,<sup>7</sup> Stephen G. Gaffney ,<sup>7</sup> Jeffrey H. Chuang,<sup>8</sup> Sheng Li,<sup>8</sup> Francesca D. Ciccarelli,<sup>9,10</sup> Anna R. Panchenko,<sup>11,12</sup> Kate Megquier,<sup>13</sup> Sudhir Kumar,<sup>14</sup> Alex Dornburg,<sup>15</sup> James DeGregori, <sup>16</sup> and Jeffrey P. Townsend (1) \*<sup>7,17,18</sup> <sup>1</sup>Department of Medicine, Duke University Medical Center, Durham, NC <sup>2</sup>Duke Cancer Institute, Duke University Medical Center, Durham, NC <sup>3</sup>Sackler School of Graduate Biomedical Sciences, Tufts University, Medford, MA <sup>4</sup>Department of Biology, Emmanuel College, Boston, MA <sup>5</sup>Department of Anthropology, University of California, Santa Barbara, CA <sup>6</sup>Department of Biology, University of Massachusetts, Amherst, MA <sup>7</sup>Department of Biostatistics, Yale School of Public Health, New Haven, CT <sup>8</sup>The Jackson Laboratory for Genomic Medicine, Farmington, CT <sup>9</sup>Cancer Systems Biology Laboratory, The Francis Crick Institute, London, United Kingdom <sup>10</sup>King's College London, London, United Kingdom <sup>11</sup>Department of Pathology and Molecular Medicine, School of Medicine, Queen's University, Kingston, ON, Canada <sup>12</sup>Ontario Institute of Cancer Research, Toronto, ON, Canada <sup>13</sup>Broad Institute, Massachusettes Institute of Technology and Harvard University <sup>14</sup>Institute for Genomics and Evolutionary Medicine, and Department of Biology, Temple University, Philadelphia, PA <sup>15</sup>North Carolina Museum of Natural Sciences, Raleigh, NC <sup>16</sup>Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO <sup>17</sup>Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT <sup>18</sup>Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT \*Corresponding author: E-mail: Jeffrey.Townsend@Yale.edu.

Corresponding author: E-mail: Jenrey. I ownsend@ rale.

Associate editor: Arndt von Haeseler

#### Abstract

Cancer progression is an evolutionary process. During this process, evolving cancer cell populations encounter restrictive ecological niches within the body, such as the primary tumor, circulatory system, and diverse metastatic sites. Efforts to prevent or delay cancer evolution—and progression—require a deep understanding of the underlying molecular evolutionary processes. Herein we discuss a suite of concepts and tools from evolutionary and ecological theory that can inform cancer biology in new and meaningful ways. We also highlight current challenges to applying these concepts, and propose ways in which incorporating these concepts could identify new therapeutic modes and vulnerabilities in cancer.

Key words: cancer, fitness landscapes, metastasis, genomics, tumor phylogenetics, comparative oncology.

The vast majority of cancer-related deaths occur in the context of metastatic spread of therapy-resistant cell lineages; and the progression from normal tissue to a localized, treatment-responsive, metastatic, and therapy-resistant disease is fundamentally an evolutionary process (Nowell 1976). During this process a diverse population of cancer cells is subject to selective forces encountered within the tissue ecology of the body. Restrictions on space (Chkhaidze et al. 2019), nutrients (Lyssiotis and Kimmelman 2017), oxygen (Amend and Pienta 2015), and other microenvironmental factors all select on clonal molecular variants within the primary tumor. These microenvironmental conditions can also induce a migratory and invasive phenotype that promotes tumor cell dissemination (Jung et al. 2015; Jolly et al. 2017) and subsequent metastatic diversification in novel environments (reviewed in Labelle and Hynes 2012). In addition to the environments encountered within the primary and metastatic niche, therapy also imposes an intense selective pressure on cancer cells, sometimes focused on individual genes or gene domains, and often leads to rapid emergence of therapy-resistant subclones (Enriquez-Navas et al. 2016).

While the population diversity subject to selective forces is most often associated with genetic diversity (Ku et al. 2017; Mu et al. 2017), other factors also can create phenotypic

<sup>©</sup> The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

diversity within a cancer cell population. These factors include DNA and histone modification (S. Li et al. 2016), transcriptional (Puram et al. 2017; Peng et al. 2019), and posttranscriptional regulation (Shapiro et al. 2011; Jolly et al. 2016; Pradella et al. 2017), and transcriptional noise (Han et al. 2016). Selection acts on phenotypes-not directly on genotypes—and the phenotype conferred by a genotype can be highly context-dependent. Thus, no matter the source of (epi)genetic and transcriptional diversity, it is the overall phenotypic behavior of the cell that determines its persistence and fate in a cell population. Critically important phenotypes of cancer have been categorized as "Cancer Hallmarks": an assortment of phenotypic traits in common across nearly all cancers (Hanahan and Weinberg 2000, 2011). These hallmarks of cancer include genome instability and mutation, sustained proliferative signaling, evading growth suppressors, enabling replicative immortality, resisting cell death, inducing angiogenesis, deregulating cellular energetics, tumor-promoting inflammation, avoiding immune destruction, and activating invasion and metastasis (Hanahan and Weinberg 2011).

An instructive parallel can be drawn between the convergent evolution in cancer phenotypes towards cancer hallmarks and the phenotypic convergence observed in cave-adapted fish (Gatenby et al. 2011). The diversity of cave-adapted fish throughout the world is the result of dozens of independent evolutionary habitat transitions by lineages that span the teleost Tree of Life. Nevertheless, virtually all obligate cavefish species have converged upon similar phenotypic hallmarks that provide adaptive advantages in cave environments (Gatenby et al. 2011), a pattern of convergence that is remarkable considering these fishes span divergences that in some cases exceed the origin of mammals (Near et al. 2012). Like cavefish, many cancer types are extremely genetically diverse, but they also converge under intense selective pressure upon certain hallmarks that enable their survival.

The phenotypic convergence onto the hallmarks of cancer observed across cancer types can be associated with molecular convergence as well. Sequencing has revealed common driver mutations in the same oncogene or tumor suppressor across different cancers. Common mutations in the TP53 DNA binding domain, KRAS G12 and G13, and domains of EGFR and PIK3CA are enriched across both individual patients and multiple cancer types (Bailey et al. 2018). Convergences such as these manifest as oncogenic hotspots and tumor suppressors with high mutation loads—molecular evidence of the intense but context-dependent selective pressures on cancer cell lineages within tissues and growing tumors (Fortunato et al. 2017).

# Integrating Evolutionary Paradigms into Cancer Research

Understanding cancer from the lens of evolutionary theory is essential to fully comprehend cancer's behavior. Herein we present a perspective on cancer and evolution that resulted from discussion during our SMBE-sponsored satellite meeting on the molecular biology and evolution of cancer. We highlight below fields of study in which evolutionary biology and cancer research naturally intersect and present a summary of potential solutions to some of the most pressing questions related to cancer and evolution (fig. 1).

#### Cross-Species Analyses of Cancer Reveals New Insights

The study of naturally-occurring cancers across species provides a unique perspective on cancer biology (Wong et al. 2019). The core clinical and molecular similarities between cancer across species have supported the longstanding use of animals with spontaneously-occurring cancers to better understand mechanistic drivers of tumors. In small animal patients, such as dogs, the similarities to humans in disease presentation, response to treatment, and the development of drug-resistance and metastasis provide an opportunity to interrogate points of therapeutic intervention and generate a thorough preclinical assessment of novel treatments.

To optimize future comparative efforts, significant energy has been placed in characterizing the genomic landscape of multiple canine cancers. Notably, while many canine cancers exhibit a similar genomic landscape to their human counterparts, novel features of the disease in dogs may also help explain some of the differences in behavior of these diseases between species. For example, recent characterization of the genomic landscape of osteosarcoma in pet dogs revealed a similar mutation burden and complex spectrum of structural aberrations to that recognized in pediatric human osteosarcoma. However, unique features of osteosarcoma in dogs, such as mutations in the epigenetic regulator, SETD2, and deletions in DMD, the gene encoding dystrophin, may help explain the more aggressive disease biology recognized in canine osteosarcoma (Perry et al. 2014; Sakthikumar et al. 2018; Gardner et al. 2019). These canine-specific molecular alterations may inform on the biology of aggressive disease or pinpoint a unique molecular subtype of aggressive human osteosarcoma. Additional examples of canine cancers with shared disease biology in people include diffuse large B-cell lymphoma and leukemias, urothelial carcinomas, and soft tissue sarcomas, among others. For example, whole-exome sequencing and RNA-sequencing of golden retrievers with hemangiosarcoma revealed similar aberrations in genes and signaling pathways (Megquier et al.). These efforts often leverage the extensive tracts of linkage disequilibrium within breeds of dogs—driven by selective inbreeding—to map molecular variants that predispose them to cancer (Sutter et al. 2004; Lindblad-Toh et al. 2005; Ostrander and Wayne 2005).

Across mammalian species, incidences of cancer are highly heterogeneous. For example, while cancer is the most common cause of death in dogs over 10 years of age, with many cancers observed at a higher incidence in dogs compared with people, other mammals, such as naked mole rats and elephants, are recognized to have a lower incidence of cancer (Tollis, Boddy, et al. 2017; Tollis, Schiffman, et al. 2017). Nevertheless, comparative investigations of cancer between species are still limited; however, emerging studies are shedding light on the mechanisms of cancer protection in some species. Investigations of elephant genomes revealed copy number gains in the tumor suppressor, *TP53*, a discovery that has since guided comparative research efforts to

### MBE




Fig. 1. Current challenges in understanding cancer proposed by attendees at the 2019 SMBE Satellite Conference on the Molecular Biology and Evolution of Cancer.

interrogate the role of tumor suppressor genes (Abegglen et al. 2015; Sulak et al. 2016). Additionally, animals living under protected conditions (e.g., humans, domesticated, zoo/aquarium, and laboratory animals) represent a potential boon of model systems to investigators. These animals are far more likely to reach ages where cancers are much more common and in some cases can also experience modern exposures (e.g., cigarette smoking) that enhance cancer risk (Hochberg and Noble 2017). By leveraging the unique features of cancer across multiple species, we have an unprecedented opportunity to advance future comparative and translational research efforts, thereby improving both our understanding of cancer biology and clinical outcomes for all patients.

## Phylogenetic Evolution of Tumor Progression and Metastasis

Given the fundamental importance of evolutionary paradigms in cancer, tools, and concepts designed to study evolutionary relationships (Darriba et al. 2018) are well suited to studies of cancer evolution (Somarelli et al. 2017). For example, incorporating molecular phylogenetic frameworks has led to improvements in imputation of missing base calls in singlecell sequencing data (Miura, Huuki, et al. 2018), and prediction of subclonal architecture from bulk sequencing data (Fischer et al. 2014; Miura, Gomez, et al. 2018). Studies applying low-pass whole-genome sequencing to circulating tumor DNA have demonstrated the feasibility of applying phylogenetic tools and evolutionary principles to track clonal dynamics during the evolution of chemotherapy resistance (Davidson et al. 2019). Whole-genome or whole-exome sequences can be used with slight modifications of classical methods of phylogenetic inference to reconstruct chronograms of cancer evolution (Zhao et al. 2016). Furthermore, analysis of ancestral states can be highly informative regarding the sequence of events underlying tumorigenesis, metastasis, and the evolution of resistance. Superposition of these temporally granular investigations of the molecular evolution of cancer with patient clinical information provides tremendous insight into the biological and clinical time course of cancer, yielding patient-specific cancer histories and common trajectories of specific cancer types. Continued development of tools grounded in evolutionary principles, coupled with further innovations in sequencing technologies, may help stratify patients for clinical trials and/or identify new actionable targets for therapeutic intervention. One area with intense research activity has been the estimation of clonal history (Beerenwinkel et al. 2015; Turajlic et al. 2015; Miura, Gomez, et al. 2018) and concomitant inference of selection (Williams et al. 2016, 2018; Tarabichi et al. 2018) using variant frequency data from tumor sequencing, an enterprise made especially challenging by cancer's special molecular characteristics-clonal growth and competition, loss of heterozygosity, rampant copy number variation, and epigenetic effects. Extensive research is needed to adapt and develop molecular phylogenetic methods well suited for analyzing extensive tumor variation that can be much more complex than sequence variation in the analysis of natural populations and species.

Leveraging Evolutionary Fitness Landscapes in Cancer Just as fitness represents the ability of an organism to survive and create genetically related offspring, it can also represent such competitive ability for cell lineages within an individual. Recognition of evolutionary selection as a metric of cancer driver genes' relative importance led to the calculation of scaled selection coefficients as a means of ranking the effects of cancer drivers (Cannataro, Gaffney, and Townsend 2018; Cannataro et al. 2019). However, the fitness of a phenotype conferred by these variants is determined not only just by

their genotype, but also by resource availability (Yun et al. 2009; Zapata et al. 2018; Bhandari et al. 2019) and epistatic interactions (Wilkins et al. 2018; van de Haar et al. 2019). Therefore, fitness landscapes can shift when resource availability or the environment change to favor a subpopulation that is, by chance, better adapted to those new conditions. In the context of cancer, resources and environments are everchanging. One key driver of this dynamic environment is age: inflammatory, metabolic, and mitochondrial functions change dramatically in older individuals (Davizon-Castillo et al. 2019), and mutation accumulation with age is expected to drive declines in cell renewal potential in tissues, particularly those with high turnover (Cannataro et al. 2016). These age-related changes in tissue architecture and function can alter the selective regime operating on stem or other progenitor cells. Henry et al. (2015) demonstrated that agingassociated increases in inflammation reduce the fitness of B-progenitor cells, promoting selection for progenitors with oncogenic mutations that restored their fitness, and leading to increased leukemias. As a malignancy expands, it creates additional microenvironmental hurdles that increase selection for adaptive genetic/phenotypic changes (Gatenby and Gillies 2008), some of which engender specific cancer hallmarks. Therefore, studies of gene-by-environment regulation and evolution across tissue and tumor microenvironments could form a basis for novel approaches that reduce cancer initiation and progression.

Although changing environmental conditions clearly alter tissue and tumor fitness landscapes, the phenotypic plasticity of cancer cells can also provide cells with a fitness advantage. For example, using a zebrafish metastasis model of melanoma, Heilman et al. observed that disseminated melanoma cells were unpigmented, but the metastatic colonies became differentiated and gained pigmentation once colonies were established (Gatenby and Gillies 2008; Heilmann et al. 2015). This observation is reminiscent of the epithelial-mesenchymal plasticity observed during metastatic dissemination and colonization in other solid tumors. For many epithelialderived tumors, a subset of cells undergo a phenotypic transition from epithelial-like to mesenchymal-like. This epithelial-mesenchymal transition enables cells to migrate, invade, and disseminate; however, the increased invasive behavior as a mesenchymal-like cell comes at a cost: cells that have undergone epithelial-mesenchymal transition often slow or stop their proliferation through cell cycle arrest (Vega et al. 2004; Mejlvang et al. 2007; Hu et al. 2008). Subsequent to seeding in a new environment, though, these mesenchymal-like cells can revert back to an epithelial-like phenotype, which reawakens proliferative capacity and enables cells to colonize (Jolly et al. 2017). This phenotypic plasticity broadens the environmental conditions available to the cell and increases the cell's overall fitness under varying resources and environments.

There are clear commonalities in fitness landscapes within and across individuals that have been demonstrated by the recurrent selection for a somewhat limited set of oncogenic mutations—particularly for the same cancer type—across many individuals. Intra-individual variability in the tissue microenvironment and phenotypic plasticity of individual cells make it challenging to discover how cancer lineages converge on fitness optima. Recurrent mutations often occur on the trunk of a clonal phylogenetic tree (Zhao et al. 2016; Yates et al. 2017), indicating strong selection for a subset of oncogenic mutations early in cancer progression. This strong selection is also indicated by the association between the prevalence of observed mutations, the pathogenicity of those mutations, and the amplitude of mutations' functional impacts on proteins and pathways (M. Li et al. 2016). To connect prevalence to the landscape of differential fitness effects of new mutations requires accounting for the natural variability in mutation rate at all scales throughout the genome and between different tissue types (Cannataro, Gaffney, Stender, et al. 2018; Cannataro and Townsend 2018, 2019; Brown et al. 2019). The relative heights of the peaks in the fitness landscape of tumorigenesis may be leveraged in a clinical setting-as the peaks of the fitness landscape correspond to relative increases in division and survival potential of cancer cells, and thus directly inform decision making about clinical trials (Wilkins et al. 2018) and the potential for cancer cell adaptation to novel putative therapies (Cannataro, Gaffney, Stender, et al. 2018).

#### **Evolutionary Genomics of Cancer**

Advances in sequencing technologies and analyses have continued to illuminate the dynamics of evolutionary processes in cancer. Exome sequencing revealed not only substantial inter-patient somatic genetic diversity with greater patient sampling (Robinson et al. 2015; Armenia et al. 2018; Cannataro and Townsend 2019), but also remarkable intratumoral heterogeneity (Gerlinger et al. 2012) that can be followed by disseminated metastatic diversity (Zhao et al. 2016; Reiter et al. 2019). Subsequent studies have illustrated the evolutionary dynamics at play during the emergence of therapy resistance (Gupta et al. 2017; Armstrong et al. 2019), as well as the role of nongenetic reprogramming of stromal compartments as contributors to therapy resistance (Woolston et al. 2019). For example, Mourikis et al. (2019) used machine-learning to identify a series of "helper genes" that work together with cancer driver genes to promote esophageal cancer. These helper-driver networks converged toward the perturbation of molecular processes with wellknown roles in cancer, such as intracellular signaling and cell cycle progression. The perturbation of similar processes is therefore recurrent in highly heterogeneous cancers, further supporting the importance of convergent evolution in cancer.

#### Discovery to Action: Adopting Evolutionary Approaches to Treat Cancer

From the selection of specific life history traits that protect organisms from cancer to the evolution of therapy-resistant and prometastatic disease states within a tumor, it is clear that the initiation, persistence, and progression of cancer is deeply rooted in molecular evolution. In exploring the connections between cancer and evolution, we asked how we can 1) use our understanding of molecular evolution to inform cancer discovery; 2) build molecular evolutionary models of cancer's special characters; 3) better understand the relations between the hallmarks of cancer and cancer fitness landscapes; and 4) facilitate collaboration and communication between diverse areas of research (fig. 1). Potential solutions to each of these challenges highlight the need for a more expansive toolkit to integrate established evolutionary paradigms into existing cancer research activities as well as communication across evolutionary and clinical disciplines.

#### Evolutionary and Ecological Paradigms Help Expand the Cancer Research Toolkit

A key concept underlying organismal evolution is the idea that environment shapes both phenotypes and the fitness values of phenotypes, leading to a fitness landscape. Likewise, cancer fitness landscapes can recapitulate and model the progression of cancer and the acquisition of its hallmarks. Application of fitness landscapes to cancer evolution requires an understanding of temporal changes in normal and cancerous tissues, in part because mutation order is a critical determinant of cancer evolution (Zhao et al. 2016; Kent and Green 2017; Gomez et al. 2018) and fitness landscapes change with age (Bilousova and DeGregori 2019; Guida et al. 2019; Nguyen et al. 2019; Rozhok and DeGregori 2019) and insult (Roper et al. 2019). Multi-regional and temporal sampling and sequencing of tumors and cells will continue to be an essential resource, enabling comprehensive monitoring of the evolutionary process underlying cancer progression. Liquid biopsies, for example, provide a noninvasive method of periodically sampling the cancer genomes within a patient, including those from tumors located in multiple regions of the body (Wan et al. 2017). Integration of longitudinal sampling with liquid biopsies, evolutionary genomics, and comparative oncology can be performed by leveraging other organisms when sampling from humans is challenging. Pet dogs acquire naturally occurring cancers; their of shorter lifespan enables time- and cost-effective data collection, and their cancers exhibit considerable biological similarity to those of their human counterparts (Schiffman and Breen 2015). At the same time, multiple model systems that can reproducibly and quantitatively demonstrate intratumoral evolution in response to treatment: patient-derived xenografts can help distinguish patterns indicating selection from stochastic evolution across such multisample studies (Kim et al. 2018). These paradigms from ecology and evolutionary biology may ultimately become essential to effective medical decision making.

# Cross-Disciplinary Communication to Fuel Discovery and Innovation

Evolutionary paradigms are already well established for evolving populations of organisms and microorganisms. Because of the role of evolution in tumorigenesis, these paradigms are an invaluable resource for application to the better understanding of cancer origination, development, and biology. For example, metastasis can be studied through the lens of movement ecology, which describes how external pressures

in an organism's environment, combined with the organism's intrinsic motivations and abilities, ultimately influence migration (Amend et al. 2016). Fitness of neoplastic cells can be understood within the framework of life history theory, which suggests that limited resources necessitate tradeoffs in energy allocation to functions such as growth, maintenance, and reproduction (Boddy et al. 2018). Conceptual parallels between organismal and cancer evolution suggest that phylogenetic methods and tools can be adapted to study cancer from a genetic and ecological perspective; cancer can likewise be exploited as a molecular model to better understand fundamental evolutionary paradigms. Increased connection and communication between evolutionary ecologists, cancer biologists, and clinicians has enormous potential to make a positive impact on our understanding of cancer and ultimately reveal novel approaches to help prolong and improve the lives of cancer patients.

#### Acknowledgment

This Perspective was developed with the assistance of funding from the Society of Molecular Biology and Evolution that supported the SMBE Satellite Meeting on the Molecular Biology and Evolution of Cancer at the Yale School of Public Health, April 12–13, 2019, organized by J.S. and J.P.T. Additional support was provided by the Notsew Orm Sands Foundation to J.P.T. and by a grant from the National Institutes of Health to S.K. (LM012487).

#### References

- Abegglen LM, Caulin AF, Chan A, Lee K, Robinson R, Campbell MS, Kiso WK, Schmitt DL, Waddell PJ, Bhaskara S, et al. 2015. Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. JAMA 314(17):1850–1860.
- Amend SR, Pienta KJ. 2015. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. *Oncotarget* 6(12):9669–9678.
- Amend SR, Roy S, Brown JS, Pienta KJ. 2016. Ecological paradigms to understand the dynamics of metastasis. *Cancer Lett.* 380(1):237–242.
- Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Celine Han G, Coleman I, et al. 2018. The long tail of oncogenic drivers in prostate cancer. *Nat Genet.* 50(5):645–651.
- Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, et al. 2019. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J. Clin. Oncol. 37:1120–1129.
- Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, et al. 2018. Comprehensive characterization of cancer driver genes and mutations. *Cell* 174(4):1034–1035.
- Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F. 2015. Cancer evolution: mathematical models and computational inference. Syst. Biol. 64(1):e1–e25.
- Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah Y-J, Vujcic T, Huang X, et al. 2019. Molecular landmarks of tumor hypoxia across cancer types. *Nat Genet*. 51(2):308–318.
- Bilousova G, DeGregori J. 2019. Elimination of unfit cells in young and ageing skin. *Nature.* 568(7752):318-319.

Boddy AM, Huang W, Aktipis A. 2018. Life history trade-offs in tumors. *Curr Pathobiol Rep.* 6(4):201–207.

- Brown A-L, Li M, Goncearenco A, Panchenko AR. 2019. Finding driver mutations in cancer: elucidating the role of background mutational processes. *PLoS Comput Biol.* 15(4):e1006981.
- Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal N, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. 2019. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. *Oncogene* 38(18):3475–3487.

Cannataro VL, Gaffney SG, Stender C, Zhao Z-M, Philips M, Greenstein AE, Townsend JP. 2018. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. *Oncogene* 37(18):2444–2455.

- Cannataro VL, Gaffney SG, Townsend JP. 2018. Effect sizes of somatic mutations in cancer. J. Natl. Cancer Inst. 110(11):1171–1177.
- Cannataro VL, McKinley SA, St Mary CM. 2016. The implications of small stem cell niche sizes and the distribution of fitness effects of new mutations in aging and tumorigenesis. *Evol Appl.* 9(4):565–582.

Cannataro VL, Townsend JP. 2018. Neutral theory and the somatic evolution of cancer. *Mol Biol Evol*. 35(6):1308–1315.

Cannataro VL, Townsend JP. 2019. Wagging the long tail of drivers of prostate cancer. *PLoS Genet.* 15(1):e1007820.

- Chkhaidze K, Heide T, Werner B, Williams MJ, Huang W, Caravagna G, Graham TA, Sottoriva A. 2019. Spatially constrained tumour growth affects the patterns of clonal selection and neutral drift in cancer genomic data. *PLoS Comput Biol.* 15(7):e1007243.
- Darriba D, Flouri T, Stamatakis A. 2018. The state of software for evolutionary biology. *Mol Biol Evol.* 35(5):1037–1046.
- Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft S-Y, Rana I, Begum R, Assiotis I, et al. 2019. Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma. *Cancers* 11, http://dx.doi.org/10.3390/cancers11050736

Davizon-Castillo P, McMahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, Montenont E, Nemkov T, D'Alessandro A, et al. 2019. TNF- $\alpha$ -driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. *Blood* 134(9):727–740.

- Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, Ruiz E, Martinez G, Minton S, Gillies RJ, et al. 2016. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 8(327):327ra24.
- Fischer A, Vázquez-García I, Illingworth CJR, Mustonen V. 2014. Highdefinition reconstruction of clonal composition in cancer. *Cell Rep.* 7(5):1740–1752.
- Fortunato A, Boddy A, Mallo D, Aktipis A, Maley CC, Pepper JW. 2017. Natural selection in cancer biology: from molecular snowflakes to trait hallmarks. *Cold Spring Harb Perspect Med.* 7, http://dx.doi.org/ 10.1101/cshperspect.a029652
- Gardner HL, Sivaprakasam K, Briones N, Zismann V, Perdigones N, Drenner K, Facista S, Richholt R, Liang W, Aldrich J, et al. 2019. Canine osteosarcoma genome sequencing identifies recurrent mutations in and the histone methyltransferase gene. *Commun Biol.* 2(1):266.
- Gatenby RA, Gillies RJ. 2008. A microenvironmental model of carcinogenesis. *Nat Rev Cancer.* 8(1):56–61.

Gatenby RA, Gillies RJ, Brown JS. 2011. Of cancer and cave fish. *Nat Rev Cancer*. 11(4):237-238.

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366(10):883–892.

Gomez K, Miura S, Huuki LA, Spell BS, Townsend JP, Kumar S. 2018. Somatic evolutionary timings of driver mutations. *BMC Cancer* 18(1):85.

- Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, et al. 2019. Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst., http://dx.doi.org/10.1093/jnci/djz136.
- Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli JA, Ware KE, Gregory S, Armstrong AJ. 2017. Whole Genomic Copy Number

Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 23:1346–1357.

- van de Haar J, Canisius S, Yu MK, Voest EE, Wessels LFA, Ideker T. 2019. Identifying epistasis in cancer genomes: a delicate affair. *Cell* 177(6):1375–1383.
- Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. *Cell* 100(1):57-70.
- Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* 144(5):646-674.

Han R, Huang G, Wang Y, Xu Y, Hu Y, Jiang W, Wang T, Xiao T, Zheng D. 2016. Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer. *Oncotarget* 7(44):72011–72020.

Heilmann S, Ratnakumar K, Langdon E, Kansler E, Kim I, Campbell NR, Perry E, McMahon A, Kaufman C, van Rooijen E, et al. 2015. A quantitative system for studying metastasis using transparent zebrafish. *Cancer Res.* 75(20):4272–4282.

Henry CJ, Casás-Selves M, Kim J, Zaberezhnyy V, Aghili L, Daniel AE, Jimenez L, Azam T, McNamee EN, Clambey ET, et al. 2015. Agingassociated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. J Clin Invest. 125(12):4666–4680.

- Hochberg ME, Noble RJ. 2017. A framework for how environment contributes to cancer risk. *Ecol Lett.* 20(2):117–134.
- Hu C-T, Wu J-R, Chang TY, Cheng C-C, Wu W-S. 2008. The transcriptional factor Snail simultaneously triggers cell cycle arrest and migration of human hepatoma HepG2. J Biomed Sci. 15(3):343–355.
- Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H. 2016. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7(19): 27067–27084.
- Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. 2017. EMT and MET: necessary or permissive for metastasis? *Mol Oncol.* 11(7):755–769.
- Jung H-Y, Fattet L, Yang J. 2015. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. *Clin Cancer Res.* 21(5):962–968.
- Kent DG, Green AR. 2017. Order matters: the order of somatic mutations influences cancer evolution. Cold Spring Harb Perspect Med. 7:a027060.
- Kim H, Kumar P, Menghi F, Noorbakhsh J, Cerveira E, Ryan M, Zhu Q, Ananda G, George J, Chen HC, et al. 2018. High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci Rep. 8(1):17937.
- Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, et al. 2017. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science* 355(6320):78–83.
- Labelle M, Hynes RO. 2012. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. *Cancer Discov.* 2(12):1091–1099.

Li M, Kales SC, Ma K, Shoemaker BA, Crespo-Barreto J, Cangelosi AL, Lipkowitz S, Panchenko AR. 2016. Balancing protein stability and activity in cancer: a new approach for identifying driver mutations affecting CBL ubiquitin ligase activation. *Cancer Res.* 76(3):561–571.

- Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, et al. 2016. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nat Med.* 22(7):792–799.
- Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, 3rd Zody MC, et al. 2005. Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* 438(7069):803–819.
- Lyssiotis CA, Kimmelman AC. 2017. Metabolic interactions in the tumor microenvironment. *Trends Cell Biol.* 27(11):863–875.
- Megquier K, Turner-Maier J, Swofford R, Kim J-H, Sarver AL, Wang C, Sakthikumar S, Johnson J, Koltookian M, Lewellen M, et al. Genomic analysis reveals shared genes and pathways in human and canine angiosarcoma. BioRxiv 570879 [Preprint]. 15 March 2019 [cited 4 Nov 2019]. Available from: https://doi.org/10.1101/570879.

- Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E. 2007. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. *MBoC* 18(11):4615–4624.
- Miura S, Gomez K, Murillo O, Huuki LA, Vu T, Buturla T, Kumar S. 2018. Predicting clone genotypes from tumor bulk sequencing of multiple samples. *Bioinformatics* 34:4017–4026.
- Miura S, Huuki LA, Buturla T, Vu T, Gomez K, Kumar S. 2018. Computational enhancement of single-cell sequences for inferring tumor evolution. *Bioinformatics* 34(17):i917–i926.
- Mourikis TP, Benedetti L, Foxall E, Temelkovski D, Nulsen J, Perner J, Cereda M, Lagergren J, Howell M, Yau C, et al. 2019. Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. *Nat Commun.* 10(1):3101.
- Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z, et al. 2017. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. *Science* 355(6320):84–88.
- Near TJ, Eytan RI, Dornburg A, Kuhn KL, Moore JA, Davis MP, Wainwright PC, Friedman M, Smith WL. 2012. Resolution of rayfinned fish phylogeny and timing of diversification. *Proc Natl Acad Sci U S A*. 109(34):13698–13703.
- Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C. 2019. Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. *Breast Cancer Res.* 21(1):25.
- Nowell PC. 1976. The clonal evolution of tumor cell populations. *Science* 194(4260):23–28.
- Ostrander EA, Wayne RK. 2005. The canine genome. *Genome Res.* 15(12):1706-1716.
- Peng J, Sun B-F, Chen C-Y, Zhou J-Y, Chen Y-S, Chen H, Liu L, Huang D, Jiang J, Cui G-S, et al. 2019. Single-cell RNA-seq highlights intratumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. *Cell Res.* 29(9):725–738.
- Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, et al. 2014. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. *Proc Natl Acad Sci U S A*. 111(51):E5564–E5573.
- Pradella D, Naro C, Sette C, Ghigna C. 2017. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. *Mol Cancer*. 16(1):8.
- Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, et al. 2017. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* 171(7):1611–1624.e24.
- Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, Azad NS, Kinzler KW, Nowak MA, Vogelstein B. 2019. An analysis of genetic heterogeneity in untreated cancers. *Nat. Rev. Cancer*1–12. (doi: 10.1038/s41568-019-0185-x; PMID: 31455892).
- Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G, et al. 2015. Integrative clinical genomics of advanced prostate cancer. *Cell* 162(2):454.
- Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown A-L, et al. 2019. APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. *Cell Rep.* 26(10):2651–2666.e6.
- Rozhok A, DeGregori J. 2019. A generalized theory of age-dependent carcinogenesis. Elife 8:e39950.
- Sakthikumar S, Elvers I, Kim J, Arendt ML, Thomas R, Turner-Maier J, Swofford R, Johnson J, Schumacher SE, Alföldi J, et al. 2018. SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma. *Cancer Res.* 78:3421.
- Schiffman JD, Breen M. 2015. Comparative oncology: what dogs and other species can teach us about humans with cancer. *Phil Trans R Soc B* 370: 20140231.

- Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. 2011. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. *PLoS Genet.* 7(8):e1002218.
- Somarelli JA, Ware KE, Kostadinov R, Robinson JM, Amri H, Abu-Asab M, Fourie N, Diogo R, Swofford D, Townsend JP. 2017. PhyloOncology: understanding cancer through phylogenetic analysis. *Biochim Biophys Acta Rev Cancer* 1867(2):101–108.
- Sulak M, Fong L, Mika K, Chigurupati S, Yon L, Mongan NP, Emes RD, Lynch VJ. 2016. Correction: tP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. *Elife* 5:e119954.
- Sutter NB, Eberle MA, Parker HG, Pullar BJ, Kirkness EF, Kruglyak L, Ostrander EA. 2004. Extensive and breed-specific linkage disequilibrium in *Canis familiaris. Genome Res.* 14(12):2388–2396.
- Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F, Spellman PT, Morris QD, Lingjærde OC, Wedge DC, Van Loo P. 2018. Neutral tumor evolution? *Nat Genet.* 50(12):1630–1633.
- Tollis M, Boddy AM, Maley CC. 2017. Peto's Paradox: how has evolution solved the problem of cancer prevention? *BMC Biol.* 15:60.
- Tollis M, Schiffman JD, Boddy AM. 2017. Evolution of cancer suppression as revealed by mammalian comparative genomics. *Curr Opin Genet Dev.* 42:40–47.
- Turajlic S, McGranahan N, Swanton C. 2015. Inferring mutational timing and reconstructing tumour evolutionary histories. *Biochim Biophys* Acta 1855:264–275.
- Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. 2004. Snail blocks the cell cycle and confers resistance to cell death. *Genes Dev.* 18(10):1131–1143.
- Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. 2017. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nat Rev Cancer* 17(4):223–238.
- Wilkins JF, Cannataro VL, Shuch B, Townsend JP. 2018. Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. *Oncotarget*. 9(32):22243–22253.
- Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. 2016. Identification of neutral tumor evolution across cancer types. *Nat Genet.* 48(3):238–244.
- Williams MJ, Werner B, Heide T, Curtis C, Barnes CP, Sottoriva A, Graham TA. 2018. Quantification of subclonal selection in cancer from bulk sequencing data. *Nat Genet.* 50(6):895–903.
- Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, et al. 2019. Crossspecies genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. *Nat Commun.* 10(1):353.
- Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, et al. 2019. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. *Cancer Cell*. 36(1):35–50.e9.
- Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, et al. 2017. Genomic evolution of breast cancer metastasis and relapse. *Cancer Cell* 32(2):169–184.e7.
- Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JKV, Markowitz S, Zhou S, et al. 2009. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 325(5947):1555–1559.
- Zapata L, Pich O, Serrano L, Kondrashov FA, Ossowski S, Schaefer MH. 2018. Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. *Genome Biol.* 19(1):67.
- Zhao Z-M, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP. 2016. Early and multiple origins of metastatic lineages within primary tumors. *Proc Natl Acad Sci U S A*. 113(8):2140–2145.